title: Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding.
abstract: Serotonin reuptake inhibitors (SRIs) increase the risk of abnormal bleeding by lowering platelet serotonin and hence the efficiency of platelet-driven hemostasis; by increasing gastric acidity and possibly gastric ulceration; and by other mechanisms. The upper gastrointestinal tract is the commonest site of SRI-related abnormal bleeding; bleeding at this location may be increased by concurrent nonsteroidal anti-inflammatory drug therapy and by treatment with antiplatelet or anticoagulant drugs. Bleeding at this location may be reduced by concurrent administration of acid-suppressing drugs.
authors: Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bangalore 560 029, India. Electronic address: andradec@gmail.com.
authors: Chittaranjan
authors: C
authors: Andrade
authors: Department of Psychiatry, King George's Medical University, Lucknow 226 003, India.
authors: Eesha
authors: E
authors: Sharma
mesh_terms: D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced*; D006801:Humans; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors
keywords: Antidepressant; Antiplatelet drugs; Bleeding; Intracranial hemorrhage; Nonsteroidal anti-inflammatory drugs; Postpartum hemorrhage; Selective serotonin reuptake inhibitor; Serotonin reuptake inhibitor